I propose to take Questions Nos. 257 and 258 together.
As the Deputy is aware, considerable investment has taken place in the Cork centre. My Department made available capital grants of more than £500,000 to complete the following works: a new components processing laboratory; a new product storage area; an upgrade of the donor clinic and new office accommodation. Furthermore, the board of the IBTS, at its meeting in January, approved a draft planning brief for a new transfusion centre in Cork for submission to my Department. My Department will reply to this request shortly with a view to providing a new state of the art facility as a matter of priority. A new IT system will be operational shortly, which is the world leader in systems for transfusion centres. The staff of the Cork centre have taken the lead role in the implementation of this key project. Additional IT and quality assurance staff have been appointed. A second consultant haematology post has been approved, and funding has been made available for this appointment.
On 5 February 2001, I announced the issue of A Guideline for the Transfusion of Red Blood Cells in Surgical Patients which has been produced by the national blood users group. The membership of this group, established by my predecessor, comprises blood user experts from hospitals nationally. The guideline states that the use of proven strategies that reduce exposure to donated blood should be made widely available and applied where appropriate. Such strategies include autologous transfusion techniques and surgical, anaesthetic and pharmacological approaches that reduce blood loss. My Department is currently making this guideline available to all hospitals, general practitioners and medical schools. A special board meeting of the IBTS is scheduled for 28 February 2001 to consider further strategies to address the concerns of the possible transmission of variant CJD – vCJD – by blood transfusion. These strategies include: deferral of some donors; replacement of products currently manufactured by the IBTS, including red cells, by products sourced in BSE-free countries; and optimal use of blood components. These developments will have major repercussions for the core business of the IBTS.